Astellas Pharma, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Astellas Pharma, Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Astellas Pharma, Inc. and its competitors. This provides our Clients with a clear understanding of Astellas Pharma, Inc. position in the Pharmaceuticals and Biotechnology Industry.

Scope

• The report contains the company’s profile and data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• The SWOT-analysis provides information about the company’s strengths, weaknesses, opportunities, and possible threats against it.
• The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency.
• It also shows the company’s income statement and ratio trend-charts, with balance sheets and cash flows presented on an annual and quarterly basis.
• Company’s financial ratios are directly compared with those of its competitors through industry averages.
• The report provides relevant news, an analysis of PR-activity, and stock price movements.
• The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms.

The benefits of buying the Report are as follows:

• Readers will gain an unrivalled in-depth knowledge about the company.
• The report will help the management of your business environment. This will be achieved through the report’s unique analysis of both the market and company’s competitors, and by providing detailed information about the internal and external factors that affect the relevant industry.
• Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• The report will help you to find prospective partners and suppliers.
• The annual profitability data provided in the report will assist and strengthen your company’s decision-making processes.

About Astellas Pharma, Inc.

Astellas Pharma, Inc. engages in the manufacture, marketing, and import/export of pharmaceuticals products in Japan. It primarily focuses on the development of products in the areas of urology, immunology and allergy, cardiovascular and diabetes, gastrointestinal and motor organs, infectious diseases, and central nervous system.

Products

The company’s products include Prograf, for the prevention and treatment of organ rejection after liver and kidney transplants; Protopic, for the treatment of atopic dermatitis; Adenoscan, a pharmacologic stress imaging agent; AmBisome, a systemic antifungal agent; Micafungin, an injectable antifungal agent; and Vaprisol, a trfeatment for euvolemic hyponatremia. Its products also include Lipitor, for the treatment of hypercholesterolemia; Gaster, for the treatment of peptic ulcers and gastritis; Harnal, for functional symptoms associated with benign prostatic hyperplasia; the hypnotic Myslee; Seroquel, an antipsychotic; Funguard, a candin antifungal agent; and Micardis, a long-acting angiotensin I receptor antagonist. In addition, the company markets Omnic/Omnic OCAS, for the treatment of the functional symptoms of benign prostatic hyperplasia; Vesicare, for overactive bladder disease and urinary incontinence; and Eligard, a treatment for advanced prostate cancer. It primarily operates in Japan, North America, Europe, and Asia. Astellas Pharma has collaborations with MerLion Pharmaceuticals Pte, Ltd. for the discovery of new drug candidates from natural substances; Theravance, Inc. for the development and commercialization of Theravance's investigational antibiotic, telavancin; and Kirin Brewery Co., Ltd. for developing and marketing a human anti-CD40 antagonistic monoclonal antibody worldwide.

Significant Events

Kirin Brewery Co., Ltd. and Astellas Pharma, Inc. have entered into a license and collaborative research and development agreement under which Kirin and Astellas would collaborate in developing and marketing a fully human anti-CD40 antagonistic monoclonal antibody worldwide.

The company has launched Advagraf (tacrolimus prolonged-release) in the UK and Germany for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for the treatment of allograft rejection resistant to treatment with other immunosuppressive drugs. Advagraf is a once-daily formulation of Prograf (tacrolimus, twice-daily formulation), the immunosuppressive agent.

Astellas Pharma, Inc. and CoMentis, Inc. announced that the companies have entered into a worldwide collaboration agreement to develop and commercialize products from CoMentis' beta-secretase inhibitor program, including CoMentis' lead candidate compound CTS-21166, an orally bioavailable, small-molecule beta-secretase inhibitor which is being developed as a disease-modifying treatment for Alzheimer's disease. The agreement also includes a research collaboration to develop additional beta-secretase inhibitors.

On July 1, 2009, Maxygen Inc. announced that Astellas Pharma Inc. and Maxygen have executed an agreement to establish a joint venture focused on the discovery, research and development of multiple protein pharmaceutical programs, including Maxygen's MAXY-4 program and other early stage programs. As part of the arrangement, Maxygen would provide Astellas with an option to acquire all of Maxygen's ownership interest in the joint venture within three years after establishment of the joint venture.

On July 22, 2009, REGiMMUNE Corporation announced that Astellas Pharma Inc. and REGiMMUNE have entered into a collaboration agreement to jointly research and develop a novel vaccine-platform technology.

In July 2009, Astellas Pharma, Inc. has opened a subsidiary in the capital city of Sao Paulo (Brazil). This opening consolidates Astellas' presence within its BRIC markets, including Russia, China and India. Astellas Farma Brasil would concentrate upon imports and distribution of medications. Benign prostatic hyperplasia drugs Omnic (tamsulosin hydrochloride) and Omnic OCAS (tamsulosin-OCAS) would be the first products to be launched in Brazil.

The company has formed a joint venture with Maxygen Inc. to develop multiple protein pharmaceutical programmes, including Maxygen's MAXY-4, for the treatment of autoimmune diseases and transplant rejection.

The company and Maxygen, Inc. have established a joint venture, Perseid Therapeutics LLC, to focus on the discovery, research, and development of multiple protein pharmaceutical programs.

On October 27, 2009, Astellas Pharma Inc. and Medivation Inc. announced that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is being evaluated in the Phase 3 AFFIRM clinical trial in men with castration-resistant prostate cancer.

On December 18, 2009, Ambit Biosciences Corporation and Astellas Pharma, Inc. announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. This partnership includes AC220, Ambit's lead clinical-stage investigational drug that entered into a Phase 2 clinical trial earlier this month in relapsed/refractory acute myeloid leukemia (AML), and other undisclosed FLT3 kinase inhibitors.

History

Astellas Pharma, Inc. was founded in 1923.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. ASTELLAS PHARMA, INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. ASTELLAS PHARMA, INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. ASTELLAS PHARMA, INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. ASTELLAS PHARMA, INC. FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. ASTELLAS PHARMA, INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Astellas Pharma, Inc. Direct Competitors
5.2. Comparison of Astellas Pharma, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Astellas Pharma, Inc. and Direct Competitors Stock Charts
5.4. Astellas Pharma, Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Astellas Pharma, Inc. Industry Position Analysis

6. ASTELLAS PHARMA, INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. ASTELLAS PHARMA, INC. EXPERTS REVIEW

7.1. Experts Opinion
7.2. Experts Estimates

APPENDIX 1: RATIO DEFINITIONS

LIST OF TABLES

Table 1. Astellas Pharma, Inc. Key Facts
Table 2. Astellas Pharma, Inc. Profitability
Table 3. Astellas Pharma, Inc. Management Effectiveness
Table 4. Astellas Pharma, Inc. Income Statement Key Figures
Table 5. Astellas Pharma, Inc. Balance Sheet Key Figures
Table 6. Astellas Pharma, Inc. Cash Flow Statement Key Figures
Table 7. Financial Performance Abbreviation Guide
Table 8. Astellas Pharma, Inc. Key Executives
Table 9. Astellas Pharma, Inc. Key Executives Biographies *
Table 10. Astellas Pharma, Inc. Key Executives Compensations *
Table 11. Astellas Pharma, Inc. Key Executives Stock Options *
Table 12. Astellas Pharma, Inc. Major Shareholders
Table 13. Astellas Pharma, Inc. History
Table 14. Astellas Pharma, Inc. Products
Table 15. Astellas Pharma, Inc. Revenues by Product
Table 16. Astellas Pharma, Inc. Revenues by Region
Table 17. Astellas Pharma, Inc. Offices and Representations
Table 18. Astellas Pharma, Inc. SWOT Analysis
Table 19. Astellas Pharma, Inc. Income Statement 2008-2011 Including 4-years Trends
Table 20. Astellas Pharma, Inc. Income Statement Latest 4 Quarters Including Trends
Table 21. Astellas Pharma, Inc. Balance Sheet 2008-2011 Including Trends
Table 22. Astellas Pharma, Inc. Balance Sheet Latest 4 Quarters Including Trends
Table 23. Astellas Pharma, Inc. Cash Flow 2008-2011 Including Trends
Table 24. Astellas Pharma, Inc. Cash Flow Latest 4 Quarters Including Trends
Table 25. Astellas Pharma, Inc. Profitability Ratios
Table 26. Astellas Pharma, Inc. Margin Analysis Ratios
Table 27. Astellas Pharma, Inc. Asset Turnover Ratios
Table 28. Astellas Pharma, Inc. Credit Ratios
Table 29. Astellas Pharma, Inc. Long-Term Solvency Ratios
Table 30. Astellas Pharma, Inc. Financial Ratios Growth Over Prior Year
Table 31. Astellas Pharma, Inc. Capital Market Snapshot
Table 32. Astellas Pharma, Inc. Direct Competitors Key Facts
Table 33. Astellas Pharma, Inc. Direct Competitors Profitability Ratios
Table 34. Astellas Pharma, Inc. Direct Competitors Margin Analysis Ratios
Table 35. Astellas Pharma, Inc. Direct Competitors Asset Turnover Ratios
Table 36. Astellas Pharma, Inc. Direct Competitors Credit Ratios
Table 37. Astellas Pharma, Inc. Direct Competitors Long-Term Solvency Ratios
Table 38. Pharmaceuticals and Biotechnology Industry Statistics
Table 39. Astellas Pharma, Inc. Industry Position
Table 40. Astellas Pharma, Inc. vs. Industry Income Statement Analysis
Table 41. Astellas Pharma, Inc. vs. Industry Balance Sheet Analysis
Table 42. Astellas Pharma, Inc. vs. Industry Cash Flow Analysis
Table 43. Astellas Pharma, Inc. vs. Industry Ratios Comparison
Table 44. Astellas Pharma, Inc. Consensus Recommendations*
Table 45. Astellas Pharma, Inc. Analyst Recommendation Summary*
Table 46. Astellas Pharma, Inc. Price Target Summary*
Table 47. Astellas Pharma, Inc. Experts Recommendation Trends*
Table 48. Astellas Pharma, Inc. Revenue Estimates Analysis*
Table 49. Astellas Pharma, Inc. Earnings Estimates Analysis*
Table 50. Astellas Pharma, Inc. Historical Surprises*
Table 51. Astellas Pharma, Inc. Revenue Estimates Trend*
Table 52. Astellas Pharma, Inc. Earnings Estimates Trend*
Table 53. Astellas Pharma, Inc. Revenue Revisions*
Table 54. Astellas Pharma, Inc. Earnings Revisions*

LIST OF FIGURES

Figure 1. Astellas Pharma, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Figure 2. Astellas Pharma, Inc. Profit Margin Chart
Figure 3. Astellas Pharma, Inc. Operating Margin Chart
Figure 4. Astellas Pharma, Inc. Return on Equity (ROE) Chart
Figure 5. Astellas Pharma, Inc. Return on Assets (ROA) Chart
Figure 6. Astellas Pharma, Inc. Debt to Equity Chart
Figure 7. Astellas Pharma, Inc. Current Ratio Chart
Figure 8. Astellas Pharma, Inc. 1-year Stock Charts
Figure 9. Astellas Pharma, Inc. 5-year Stock Charts
Figure 10. Astellas Pharma, Inc. vs. Main Indexes 1-year Stock Chart
Figure 11. Astellas Pharma, Inc. vs. Direct Competitors 1-year Stock Charts
Figure 12. Astellas Pharma, Inc. Article Density Chart

* – Data availability depends on company’s security policy.
The complete financial data is available for public traded companies.

The above Company Fundamental Report is a half-ready report.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get up-to-date version for the same price.